C4 Therapeutics (CCCC) EBITDA (2019 - 2026)
C4 Therapeutics' quarterly EBITDA came in at -$25.5 million in Q1 2026, up 3.16% year-on-year from -$24.7 million in Q1 2025, and down 23.94% quarter-over-quarter from -$20.6 million in Q4 2025.
C4 Therapeutics has reported EBITDA for 8 years, with the latest figure at -$25.5 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 3.16% year-over-year to -$25.5 million; the trailing twelve-month figure through Mar 2026 stood at -$104.2 million (down 1.33% YoY), and the FY2025 full-year result was -$105.0 million, changed 0.13% from the prior year.
- EBITDA for Q1 2026 stood at -$25.5 million, down from -$20.6 million in the prior quarter.
- The five-year high for EBITDA was -$17.8 million in Q2 2024, with the low at -$35.9 million in Q4 2022.
- Average EBITDA over 5 years is -$29.2 million, with a median of -$28.6 million recorded in 2024.
- Year-over-year, EBITDA plunged 120.62% in 2022 and soared 49.54% in 2024.
- Tracing CCCC's EBITDA over 5 years: stood at -$35.9 million in 2022, then increased by 5.39% to -$34.0 million in 2023, then slipped by 2.94% to -$35.0 million in 2024, then soared by 41.17% to -$20.6 million in 2025, then slipped by 23.94% to -$25.5 million in 2026.
- The last three EBITDA figures came in at -$25.5 million (Q1 2026), -$20.6 million (Q4 2025), and -$32.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -25.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.50 Mn |
| Dec 31, 2025 | -20.58 Mn |
| Sep 30, 2025 | -32.05 Mn |
| Jun 30, 2025 | -26.09 Mn |
| Mar 31, 2025 | -26.33 Mn |
| Dec 31, 2024 | -34.98 Mn |
| Sep 30, 2024 | -23.77 Mn |
| Jun 30, 2024 | -17.78 Mn |
| Mar 31, 2024 | -28.61 Mn |
| Dec 31, 2023 | -33.98 Mn |
| Sep 30, 2023 | -26.17 Mn |
| Jun 30, 2023 | -35.23 Mn |
| Mar 31, 2023 | -33.11 Mn |
| Dec 31, 2022 | -35.91 Mn |
| Sep 30, 2022 | -32.79 Mn |
| Jun 30, 2022 | -28.34 Mn |
| Mar 31, 2022 | -34.50 Mn |
| Dec 31, 2021 | -16.28 Mn |
| Sep 30, 2021 | -24.77 Mn |
| Jun 30, 2021 | -22.56 Mn |
| Mar 31, 2021 | -21.08 Mn |
| Dec 31, 2020 | -21.79 Mn |
| Sep 30, 2020 | -21.83 Mn |
| Jun 30, 2020 | -10.80 Mn |
| Mar 31, 2020 | -11.91 Mn |
| Dec 31, 2019 | -10.02 Mn |
| Sep 30, 2019 | -10.09 Mn |